ClinicalTrials.gg
Not yet recruitingNCT07417995STRIDE-PsAUpdated May 13, 2026

A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis

An observational study in Psoriasis Arthritis, sponsored by Royal United Hospitals Bath NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Royal United Hospitals Bath NHS Foundation Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies in Psoriasis with a site in United Kingdom — 9 open to participants now, 16 under way, 9 of them phase 3. Psoriasis · United Kingdom.

Planned enrollment
12th of 21
400 · median 412
Started
2026
with 1 other
Observational
21 of 157
4 open now
Primary completion
2027-06
later than 8 of 15 live
Registered
155th of 157
by date

Among the 157 studies in Psoriasis with a site in United Kingdom, this one is the 12th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2026, is one of 21 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 155th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 157 studies in Psoriasis with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Psoriasis with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care.

The main questions are:

  • Do treatment responses differ according to the number of previous advanced therapies?
  • Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness?

Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.

Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.

Read the detailed description

Study Design and Objectives

STRIDE-PsA is a prospective, multicentre observational cohort study conducted within routine NHS rheumatology care. Approximately ten NHS sites will recruit adults with psoriatic arthritis (PsA) initiating a new biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD). Participants will be followed for 52 weeks with assessments at baseline and weeks 4, 12, 24, and 52. As this is a non-interventional study, treatment decisions and clinical management will remain at the discretion of the treating clinician.

The study aims to evaluate treatment effectiveness across different lines of advanced therapy and to investigate whether anti-drug antibodies (ADAs) or circulating drug levels are associated with clinical response. The underlying hypothesis is that patients may achieve comparable clinical improvement despite multiple prior therapy switches.

Study Procedures and Data Collection

Participants will be followed for 52 weeks with assessments aligned to routine NHS rheumatology care. Data collection will include clinical examinations, patient-reported outcome measures (PROMs), and blood sampling for ADA and drug level analysis.

At baseline, informed consent will be obtained and demographic and clinical history recorded. Participants will undergo routine clinical assessment to derive disease activity measures (including cDAPSA, BSA, and minimal disease activity status), complete validated PROMs (PSAID-9, HAQ-DI, PGADA), and provide routine NHS blood tests. An additional small research blood sample will be collected, where feasible alongside routine bloods.

Follow-up assessments will occur at approximately Weeks 4, 12, 24, and 52. PROMs will be collected at each follow-up time point, with repeat clinical examination and a second research blood sample at Week 12 during routine care visits. Information on suspected treatment-related adverse events identified during routine clinical review will be recorded throughout follow-up.

All procedures are designed to align with standard NHS appointments to minimise additional participant burden, and visit windows are permitted to allow flexibility in scheduling.

Recruitment and Follow-up

Potential participants will be identified during routine rheumatology appointments by the direct care team and provided with study information. Written informed consent will be obtained by trained research staff prior to any study-specific procedures. Participants may provide consent on the day of approach or after further consideration, according to preference.

Sample Size Rationale

The primary analysis will compare mean change in cDAPSA from baseline to Week 12 between patients initiating 4th/5th-line versus 2nd/3rd-line b/tsDMARD. The non-inferiority margin is set at -5.7 cDAPSA points, based on published estimates of the minimally clinically important difference, and the investigators assume SD = 12.36 for the 12-week change from published data. With one-sided α = 0.05 and 80% power, the required sample size is \~58 per group. Allowing for 10% drop out, this gives 65 per group, for a total of 130 participants across the two primary groups (equal allocation). Patients initiating first-line therapy and those on 6th-line or beyond will also be recruited as descriptive comparative cohorts. To ensure adequate precision for secondary endpoints (including patient-reported outcomes and quality-of-life measures) and to support regression analyses of treatment sequencing, the investigators plan to over-recruit, aiming for approximately 100 patients in each of the four groups (1st line, 2nd/3rd, 4th/5th, and 6th+; ≈400 total). Based on pilot data from Bath, which indicates around 80 patients have been commenced on b/tsDMARD therapy over a year, the investigators anticipate that recruitment from ten sites with a 50% consent rate will allow us to meet our recruitment target over 18 months.

Bias, Confounding, and Data Quality

Given the observational design, several strategies will be implemented to minimise bias. Screening logs will be maintained to evaluate recruitment patterns and potential selection bias. Analyses will adjust for pre-specified confounders, including study site, age, sex, baseline disease activity, disease duration, and comorbidities. Standardised electronic case report forms, validated PROMs, and site training will be used to reduce information bias.

Standardised data collection forms, training of research staff, and use of validated patient-reported outcome measures will minimise variation in data collection across sites. Loss to follow-up will be monitored, and reasons recorded where available. Sensitivity analyses will explore the impact of missing data, including multiple imputation where appropriate.

Statistical Analysis

The primary endpoint is change in cDAPSA score from baseline to Week 12. A non-inferiority margin of -5.7 points has been pre-specified based on published minimally clinically important difference thresholds. Change in cDAPSA will be analysed using analysis of covariance (ANCOVA), adjusting for baseline cDAPSA, age, sex, disease duration, relevant comorbidities, and study centre. A one-sided α = 0.05 will be used. Analyses will be conducted in both intention-to-treat and per-protocol populations.

Secondary endpoints will be analysed using regression models with covariate adjustment consistent with the primary analysis.

Achievement of minimal disease activity (MDA) at Week 12 and composite clinical response (cDAPSA low disease activity plus BSA \<1%) will be analysed using logistic regression. Continuous change in skin involvement (body surface area, BSA) will be analysed using analysis of covariance (ANCOVA), with logistic regression used for categorical skin response thresholds.

Patient-reported outcomes, including health-related quality of life (PsAID-9), physical function (HAQ-DI), and patient global assessment (PGADA), will be analysed using ANCOVA models adjusting for baseline values and predefined covariates.

Treatment persistence will be evaluated using Kaplan-Meier survival analysis and Cox proportional hazards regression. Flare outcomes, as measured by the PsA Flare questionnaire, will be analysed using logistic regression.

Anti-drug antibody (ADA) outcomes will be summarised descriptively, including prevalence, incidence, and titre distribution by therapy line. Exploratory analyses will assess associations between ADA status or titres, circulating drug levels, clinical response, treatment-related adverse events, and treatment persistence using appropriate multivariable models.

Missing data are anticipated due to incomplete follow-up. The primary analysis will assume data are missing at random and will use multiple imputation for continuous and binary Week-12 endpoints, incorporating baseline values and predefined covariates. Sensitivity analyses will include complete-case analyses and conservative assumptions for binary outcomes. For time-to-event endpoints, participants lost to follow-up will be right-censored at the last known treatment date, and event times will not be imputed.

03

Conditions studied

  • Psoriasis Arthritis

Browse trials for

Keywords

  • Anti-drug antibody
  • Biologic therapies
  • Immunogenicity
  • Targeted Synthetic DMARDs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with a confirmed diagnosis of PsA, meeting CASPAR classification criteria, who are initiating a new advanced therapy (b/tsDMARD) as part of routine NHS care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Clinical diagnosis of PsA meeting CASPAR criteria
  • Starting a new b/tsDMARD, irrespective of

Exclusion criteria

Exclusion Criteria:

  • Switching b/tsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis.
  • Previous treatment with the same b/tsDMARD being started at baseline.
  • Inability or unwillingness to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • First-line Advanced Therapy

    Participants with PsA initiating their first biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine NHS clinical care. Treatment is prescribed by the treating clinician and not assigned by the study.

    Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)

  • Second/Third-line Advanced Therapy

    Participants with PsA initiating a second or third b/tsDMARD following prior advanced therapy exposure. All treatments are part of routine clinical care.

    Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)

  • Fourth/Fifth-line Advanced Therapy

    Participants with PsA initiating a fourth or fifth b/tsDMARD as part of routine care after multiple prior advanced therapy switches.

    Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)

  • Sixth-line or Later Advanced Therapy

    Participants with PsA initiating a sixth or subsequent b/tsDMARD during routine clinical care.

    Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)

Interventions

  • DrugBiologic or targeted synthetic DMARD (b/tsDMARD)

    This is a non-interventional observational study. Participants will receive biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as part of routine NHS clinical care, and no treatment will be assigned by the study. Participants will be categorised into cohorts according to the line of advanced therapy being initiated at study entry (first line, second/third line, fourth/fifth line, and sixth line or beyond). The study will evaluate treatment outcomes, circulating drug levels, and anti-drug antibody (ADA) status across these treatment-line groups. All treatment decisions remain at the discretion of the treating clinician.

06

What researchers measure

Primary outcomes

  1. Clinical Disease Activity in Psoriatic Arthritis (cDAPSA)

    The cDAPSA is the primary outcome and is a validated composite measure of disease activity in PsA. It is calculated as the sum of the tender joint count (0-68 joints), swollen joint count (0-66 joints), patient global assessment of disease activity (0-10 cm visual analogue scale), and patient assessment of arthritis pain (0-10 cm VAS). Unlike the full DAPSA, cDAPSA does not include C-reactive protein. Scores provide a continuous measure of disease activity, with established thresholds to categorise disease states: remission (≤4), low disease activity (\>4-13), moderate disease activity (\>13-27), and high disease activity (\>27).

    Time frame: Weeks 0/12

Secondary outcomes

  1. Body Surface Area of Psoriasis (BSA)

    In the BSA assessment, the patient's hand (including the palm, fingers, and thumb) will be used as the reference point for measuring how much of their skin is affected by psoriasis, representing roughly 1% of the body's surface. The BSA palm method will be used for the evaluation of BSA affected by psoriasis as follows: * Head and neck=10% (10 palms) * Upper extremities=20% (20 palms) * Trunk=30% (30 palms) * Lower extremities=40% (40 palms) * Total BSA=100%

    Time frame: Week 0/12

  2. Minimal Disease Activity (MDA)

    Minimal Disease Activity (MDA) is a validated composite outcome used in psoriatic arthritis to define a state of low disease activity across the main clinical domains. A patient is considered to have achieved MDA if they meet at least 5 out of the following 7 criteria: 1. Tender joint count ≤1 2. Swollen joint count ≤1 3. Psoriasis-affected body surface area (BSA) ≤3% 4. Patient pain visual analogue scale (VAS) ≤15 mm 5. Patient global assessment of disease activity VAS ≤20 mm 6. Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤0.5 7. Tender entheseal points ≤1

    Time frame: Weeks 0/12

  3. Psoriatic Arthritis Impact of Disease-9 (PsAID-9)

    The PsAID-9 is a short, validated tool designed to capture the impact of psoriatic arthritis from the patient's perspective \[14\]. It consists of nine domains that patients rate on a 0-10 numerical rating scale, where higher scores indicate worse status. The domains are: pain, fatigue, skin problems, work/leisure activities, functional capacity, discomfort, sleep disturbance, coping, and anxiety/fear. Each domain is weighted according to its relative importance, and an overall weighted mean score (0-10) is calculated. A score below 4 is generally considered to represent a patient-acceptable symptom state.

    Time frame: Weeks 0/4/12/24/52

  4. Health Assessment Questionnaire-Disability Index (HAQ-DI)

    The HAQ-DI contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Study participants will be required to indicate the degree of difficulty they experience in each domain in the past week on a 4-point scale that ranges from 0 (without difficulty) to 3 (unable to do). The HAQ-DI score ranges from 0 to 3. A lower HAQ-DI score indicates an improvement in function.

    Time frame: Weeks 0/4/12/24/52

  5. Patients' Global Assessment of Disease Activity (PGADA VAS)

    The study participant's global assessment of disease activity (PGADA) will be performed using a 100mm visual analog scale (VAS) scale where 0 is "very good, no symptoms" and 100 is "very poor, severe symptoms". The study participant will be asked the following question: "In all the ways in which your psoriasis and arthritis, as a while, affects you, how would you rate the way you felt over the past week?". The study participant will be asked to consider his/her arthritis symptoms and functional capacity in their response to this question.

    Time frame: Weeks 0/4/12/24/52

  6. Duration of time on b/tsDMARD

    Duration on b/tsDMARD therapy will be defined as the time in weeks from the date of first dose to the date of permanent discontinuation for any reason (including inefficacy, adverse events or patient choice). Patients who remain on therapy at last follow-up will be censored at that date. If there has been any period of time off treatment deemed by the treating physician to be clinically impactful, the patient will be excluded from the study.

    Time frame: Weeks 0/4/12/24/52

  7. Patient completed disease flare questionnaire (FLARE)

    The PsA Flare Questionnaire is a validated, patient-completed tool designed to capture episodes of disease flare from the patient's perspective. It consists of ten yes/no items covering key disease domains, including: joint pain and swelling, skin psoriasis, impact of activities of daily living, mobility, frustration, depression, tiredness and a change in number or combination of symptoms from PsA. Each "yes" response scores one point, giving a total score from 0 to 10. A threshold of ≥4 has been shown to represent a clinically meaningful flare.

    Time frame: Weeks 0/4/12/24/52

  8. Anti-drug antibody (ADA) and non-trough drug levels

    ADAs will be measured using standardised, in-house sandwich enzyme-linked immunosorbent assays (ELISA) developed at the University of Bath. These assays are designed to be fully drug-tolerant, allowing detection of ADAs despite the presence of circulating drug, and include assessment of neutralising ADAs, addressing key limitations of many previous immunogenicity studies in PsA. Unlike most previous studies, which have primarily measured total ADAs alone, the investigators will also be able to characterise immunoglobulin isotypes, including IgM, IgE, IgA and IgG subclasses (IgG1-4), providing potential relevance to ADA effector mechanisms.

    Time frame: Weeks 0/12

07

Study locations

1 site
08

References and documents

Publications

  • Gollins CE, Russell A, Smith T, Vivekanantham A, Brooke M, Coates LC, Gullick N, Helliwell P, McHugh N, Fahy C, Tillett W; SEQUENCE Study Group. A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK. Rheumatology (Oxford). 2026 Feb 4;65(2):keaf570. doi: 10.1093/rheumatology/keaf570. PubMed 41206077 ↗
  • Gollins CE, Vincent R, Fahy C, McHugh N, Brooke M, Tillett W. Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2024 Jul 1;63(7):1790-1802. doi: 10.1093/rheumatology/keae006. PubMed 38243715 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 93 non-industry observational studies under Psoriasis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 119. This study's planned 12 months is below that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 18, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07417995
Lead sponsor
Royal United Hospitals Bath NHS Foundation Trust
Collaborators
University of Bath
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 13, 2026

Study contacts

James Kimpton, BA (Hons) BM BCh (oxon) MRCP
Contact
james.kimpton@nhs.net
+44 01225 824160
James Kimpton, BA (Hons) BM BCh (oxon) MRCP
principal investigator · Royal United Hospitals Bath NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion